Atrium Therapeutics, Inc. (RNA) stock
Close on Nov 13, 2026Market cap $128.46MP/E –Yield –
Atrium Therapeutics statistics
44 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- –
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 0.63
- 2.22
Share statisticsIndustry
- Shares Change (QoQ)
- -4.12%
- 0.50%
- Float
- 17M
- 49M
- Shares Held by Insiders
- 3.04%
- 11.7%
- Shares Held by Institutions
- 90.6%
- 56.4%
Short sellingIndustry
- Short Interest
- 4M
- –
- Short Interest Change
- 0.61%
- -0.80%
- Short % of Float
- 22.6%
- 9.01%
- Short % of Shares Outstanding
- 21.9%
- 6.30%
- Days to Cover
- 16.07
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $73.06
- –
- 52-Week Low
- $7.47
- –
- 20-Day Moving Average
- $8.17
- –
- 50-Day Moving Average
- $8.65
- –
- 200-Day Moving Average
- $17.65
- –
- Average True Range (14)
- $0.39
- –
- Price Change (1 Week)
- -9.95%
- -1.15%
- Price Change (1 Month)
- -3.96%
- -4.87%
- Price Change (3 Months)
- -42.1%
- -21.0%
- Price Change (6 Months)
- -43.2%
- -20.6%
- Price Change (YTD)
- -89.6%
- -23.6%
- Price Change (1 Year)
- -89.4%
- -22.4%
- Average Volume (10 Days)
- 205,855
- –
- Average Volume (20 Days)
- 224,665
- –
- Average Volume (90 Days)
- 246,950
- –
- Relative Volume
- 0.79
- 0.70
- Relative Strength Index (14)
- 32.7
- 43.4
- Volatility (1 Year)
- 90.6%
- 80.1%
- Beta (5 Years)
- 1.33
- 1.07
Financial positionIndustry
- Current Ratio
- 10.46
- 3.30
- Quick Ratio
- 9.41
- 2.39
EfficiencyIndustry
- WACC
- 11.7%
- 10.2%
Balance sheetIndustry
- Net Cash (Debt)
- $232.07M
- $17.76M
- Net Cash Per Share
- $13.57
- $0.80
- Equity (Book Value)
- $205.02M
- $53.89M
- Book Value Per Share
- $11.99
- $1.50
- Tangible Book Value
- $205.02M
- $27.13M
- Working Capital
- $233.39M
- $79.99M
Scores and fair valueIndustry
- Altman Z-Score
- 2.30
- 0.23
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | RNA | S&P 500 | Difference | RNA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.1% | -3.0% | −0.1 pts | ||
| 3 months | -39.1% | -2.8% | −36.3 pts | ||
| Year to date | -89.6% | +11.5% | −101.1 pts | ||
| 1 year | -89.4% | +13.5% | −102.9 pts |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
4M RNA shares were sold short on Oct 30, 2026, up 0.6% from the previous report, or 22.61% of the shares available to trade. At recent volumes it would take 16.1 days to buy them back. Over the last 20 sessions, 37.8% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 3,749,186 | +0.6% | 233,325 | 16.1 |
| Oct 15, 2026 | 3,726,302 | +9.7% | 288,048 | 12.9 |
| Sep 30, 2026 | 3,395,873 | -0.1% | 410,851 | 8.3 |
| Sep 15, 2026 | 3,397,791 | +1.4% | 417,130 | 8.2 |
| Aug 31, 2026 | 3,351,526 | -3.7% | 169,372 | 19.8 |
| Aug 14, 2026 | 3,480,849 | -0.9% | 126,745 | 27.5 |
| Jul 31, 2026 | 3,514,133 | -2.1% | 123,798 | 28.4 |
| Jul 15, 2026 | 3,591,224 | -1.8% | 202,748 | 17.7 |
| Jun 30, 2026 | 3,656,821 | +1.3% | 292,054 | 12.5 |
| Jun 15, 2026 | 3,610,418 | -1.2% | 177,756 | 20.3 |
| May 29, 2026 | 3,653,605 | -2.1% | 230,736 | 15.8 |
| May 15, 2026 | 3,732,204 | +8.9% | 176,203 | 21.2 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?